303 related articles for article (PubMed ID: 35045616)
1. [Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and hypertrophic cardiomyopathy].
Liu YY; Du X; He L; Hu R; Ning M; Lyu J; Dong JZ; Ma CS
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jan; 50(1):62-67. PubMed ID: 35045616
[No Abstract] [Full Text] [Related]
2. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation.
Lin Y; Xiong H; Su J; Lin J; Zhou Q; Lin M; Zhao W; Peng F
Heart Vessels; 2022 Jul; 37(7):1224-1231. PubMed ID: 35041061
[TBL] [Abstract][Full Text] [Related]
4. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
[TBL] [Abstract][Full Text] [Related]
5. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation.
Creta A; Hunter RJ; Earley MJ; Finlay M; Dhinoja M; Sporton S; Chow A; Mohiddin SA; Boveda S; Adragao P; Jebberi Z; Matos D; Schilling RJ; Lambiase PD; Providência R
J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2626-2631. PubMed ID: 32639666
[TBL] [Abstract][Full Text] [Related]
7. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.
Lee HJ; Kim HK; Jung JH; Han KD; Lee H; Park JB; Kim HM; Kim YJ; Ommen SR
Stroke; 2019 Sep; 50(9):2582-2586. PubMed ID: 31340730
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.
Corbalan R; Bassand JP; Illingworth L; Ambrosio G; Camm AJ; Fitzmaurice DA; Fox KAA; Goldhaber SZ; Goto S; Haas S; Kayani G; Mantovani LG; Misselwitz F; Pieper KS; Turpie AGG; Verheugt FWA; Kakkar AK;
JAMA Cardiol; 2019 Jun; 4(6):526-548. PubMed ID: 31066873
[TBL] [Abstract][Full Text] [Related]
10. Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin.
Shin DG; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
Yonsei Med J; 2016 Mar; 57(2):342-9. PubMed ID: 26847285
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.
Dominguez F; Climent V; Zorio E; Ripoll-Vera T; Salazar-Mendiguchía J; García-Pinilla JM; Urbano-Moral JA; Fernández-Fernández X; Lopez-Cuenca D; Ajo-Ferrer R; Sanz-Sanchez J; Gomez-Perez Y; López-Garrido MA; Barriales-Villa R; Gimeno JR; Garcia-Pavia P
Int J Cardiol; 2017 Dec; 248():232-238. PubMed ID: 28811092
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
[TBL] [Abstract][Full Text] [Related]
14. [A comparison of CAS risk model and CHA
Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement.
Wu VC; Wang CL; Gan ST; Wu M; Chen SW; Kuo CF; Huang YT; Wen MS; Chang SH
PLoS One; 2020; 15(12):e0243866. PubMed ID: 33315930
[TBL] [Abstract][Full Text] [Related]
16. Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study.
Wang CL; Wu VC; Huang YT; Kuo CF; Chu PH; Chen YL; Wen MS; Chang SH
J Am Heart Assoc; 2019 May; 8(9):e012029. PubMed ID: 31020896
[TBL] [Abstract][Full Text] [Related]
17. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry.
Schnabel RB; Ameri P; Siller-Matula JM; Diemberger I; Gwechenberger M; Pecen L; Manu MC; Souza J; De Caterina R; Kirchhof P
Europace; 2023 Aug; 25(9):. PubMed ID: 37713182
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]